![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/08/01/2922669/0/en/InflaRx-to-Report-Second-Quarter-2024-Results-on-August-8-2024.html
https://www.globenewswire.com/news-release/2024/07/30/2920901/0/en/InflaRx-to-Present-New-Preclinical-Data-on-INF904-at-the-19th-European-Meeting-on-Complement-in-Human-Diseases.html
https://www.globenewswire.com/news-release/2024/06/24/2902947/0/en/InflaRx-s-GOHIBIC-Vilobelimab-Selected-for-First-BARDA-Sponsored-Clinical-Trial-to-Evaluate-Novel-Host-Directed-Therapeutics-for-Acute-Respiratory-Distress-Syndrome-ARDS.html
https://www.globenewswire.com/news-release/2024/06/05/2894084/0/en/InflaRx-Hosts-R-D-Event-Highlighting-the-Promise-of-INF904.html
https://www.globenewswire.com/news-release/2024/05/21/2885964/0/en/InflaRx-Presents-New-Analysis-of-PANAMO-Phase-III-Trial-in-Severe-COVID-19-at-ATS-2024-Showing-Potential-Synergy-With-Vilobelimab-When-Used-in-Combination-with-Other-Immunomodulato.html
https://www.globenewswire.com/news-release/2024/05/08/2877724/0/en/InflaRx-Reports-First-Quarter-2024-Financial-Results-and-Provides-Business-Update.html
https://www.globenewswire.com/news-release/2024/04/30/2872123/0/en/InflaRx-to-Host-Virtual-R-D-Event-on-June-5-2024-and-Report-First-Quarter-2024-Results-on-May-8-2024.html
https://www.globenewswire.com/news-release/2024/04/24/2868506/0/en/InflaRx-to-Participate-in-Capital-One-Securities-1st-Annual-Biotech-Biopharma-Disrupters-Event.html
https://www.globenewswire.com/news-release/2024/03/21/2850106/0/en/InflaRx-Reports-Full-Year-2023-Results-and-Announces-INF904-Development-Plans.html
https://www.globenewswire.com/news-release/2024/03/19/2848459/0/en/InflaRx-to-Announce-Development-Plans-for-INF904-and-2023-Financial-Results-on-March-21-2024.html